Raymond James Financial
PVLA

Raymond James Financial’s Palvella Therapeutics PVLA Stock Holding History

Raymond James Financial’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.17M Buy
25,446
+3,182
+14% +$332K ﹤0.01% 2967
2025
Q4 		$2.33M Sell
22,264
-1,574
-7% -$134K ﹤0.01% 3145
2025
Q3 		$1.49M Buy
23,838
+23,833
+476,660% +$1.06M ﹤0.01% 3401
2025
Q2 		$113 Buy
+5
New +$117 ﹤0.01% 6836

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raymond James Financial's PVLA Position: Q1 2026 in Review

Raymond James Financial increased its Palvella Therapeutics (PVLA) stake by 14% in Q1 2026, buying an estimated $332K and bringing the position to 25,446 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2967.

Raymond James Financial first reported a position in PVLA in Q2 2025 and has held it in 4 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Raymond James Financial held 25,446 shares of Palvella Therapeutics worth $3.17M as of Q1 2026.
  • Raymond James Financial bought 3,182 Palvella Therapeutics shares in Q1 2026, an estimated $332K.
  • Palvella Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2967 holding.
  • Raymond James Financial first reported a position in Palvella Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.